Pharsight

Fintepla patents expiration

FINTEPLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10947183 UCB INC Fenfluramine compositions and methods of preparing the same
Dec, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9603815 UCB INC Method for the treatment of Dravet syndrome
May, 2033

(9 years from now)

US9549909 UCB INC Method for the treatment of dravet syndrome
May, 2033

(9 years from now)

US9610260 UCB INC Method for the treatment of Dravet Syndrome
May, 2033

(9 years from now)

US9603814 UCB INC Method for the treatment of Dravet syndrome
May, 2033

(9 years from now)

US10478442 UCB INC Method for the treatment of Dravet Syndrome
May, 2033

(9 years from now)

US10478441 UCB INC Method for the treatment of Dravet syndrome
May, 2033

(9 years from now)

US10478441

(Pediatric)

UCB INC Method for the treatment of Dravet syndrome
Nov, 2033

(9 years from now)

US9549909

(Pediatric)

UCB INC Method for the treatment of dravet syndrome
Nov, 2033

(9 years from now)

US10478442

(Pediatric)

UCB INC Method for the treatment of Dravet Syndrome
Nov, 2033

(9 years from now)

US9610260

(Pediatric)

UCB INC Method for the treatment of Dravet Syndrome
Nov, 2033

(9 years from now)

US9603814

(Pediatric)

UCB INC Method for the treatment of Dravet syndrome
Nov, 2033

(9 years from now)

US9603815

(Pediatric)

UCB INC Method for the treatment of Dravet syndrome
Nov, 2033

(9 years from now)

US10950331 UCB INC Control system for control of distribution of medication
Sep, 2035

(11 years from now)

US10950331

(Pediatric)

UCB INC Control system for control of distribution of medication
Mar, 2036

(11 years from now)

US10947183

(Pediatric)

UCB INC Fenfluramine compositions and methods of preparing the same
Jun, 2037

(13 years from now)

US11406606 UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(13 years from now)

US11759440 UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(13 years from now)

US11040018 UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(13 years from now)

US11786487 UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(13 years from now)

US10603290 UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(13 years from now)

US11040018

(Pediatric)

UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Feb, 2038

(13 years from now)

US11786487

(Pediatric)

UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Feb, 2038

(13 years from now)

US11759440

(Pediatric)

UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Feb, 2038

(13 years from now)

US11406606

(Pediatric)

UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Feb, 2038

(13 years from now)

US10603290

(Pediatric)

UCB INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Feb, 2038

(13 years from now)

US10452815 UCB INC Control system for control of distribution of medication
Jun, 2038

(14 years from now)

US10452815

(Pediatric)

UCB INC Control system for control of distribution of medication
Dec, 2038

(14 years from now)

Fintepla is owned by Ucb Inc.

Fintepla contains Fenfluramine Hydrochloride.

Fintepla has a total of 28 drug patents out of which 0 drug patents have expired.

Fintepla was authorised for market use on 25 June, 2020.

Fintepla is available in solution;oral dosage forms.

Fintepla can be used as method of treating seizures in a patient by administering a liquid formulation of fenfluramine or its salts plus stiripentol thereby reducing norfenfluramine formation while increasing the fenfluramine level. patients can have e.g. dravet or lgs, method of reducing or ameliorating seizures in a patient by administering a liquid formulation of fenfluramine with stiripentol thereby modulating down the formation of norfenfluramine and resulting in higher levels of fenfluramine, treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution, use in combination with stiripentol for the treatment of seizures associated with dravet syndrome, use in combination with cannabidiol for the treatment of seizures associated with lennox-gastaut syndrome, use of cardiac monitoring and restricted distribution of fenfluramine to mitigate risk of cardiovascular toxicity in the treatment of seizures associated with dravet syndrome, use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome, use of fenfluramine at reduced amounts with stiripentol for the treatment of seizures associated with lennox gastaut syndrome.

The generics of Fintepla are possible to be released after 29 December, 2038.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-312) Jun 25, 2027
New Indication(I-887) Mar 25, 2025
Orphan Drug Exclusivity(ODE-393) Mar 25, 2029
New Product(NP) Jun 25, 2023
Pediatric Exclusivity(PED) Sep 25, 2029

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 June, 2020

Treatment: Use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome; Use in combination with stiripentol for the treatment of seizures associated...

Dosage: SOLUTION;ORAL

How can I launch a generic of FINTEPLA before it's drug patent expiration?
More Information on Dosage

FINTEPLA family patents

Family Patents